StockNews.AI

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

StockNews.AI • 2 days

MDTZBHABT
High Materiality8/10

Information

MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stag...

Original source

AI Summary

CVRx has confirmed the transition of its Barostim device to Category I CPT codes, effective January 1, 2026. This change enables broader adoption and reimbursement for its innovative heart failure therapy, which is the first FDA-approved neuromodulation device in this space.

Trading Thesis

The transition to Category I CPT codes is likely to increase CVRX's market reach and revenue potential.

Market-Moving

  • Category I CPT codes could significantly boost CVRx's patient adoption rates.
  • Barostim's improved reimbursement may attract more healthcare professionals.
  • FDA approval positions Barostim favorably among heart failure therapies.
  • Increased awareness can elevate CVRX's stock price as adoption grows.
  • The expansion of use cases in the EU could drive international growth.

Key Facts

  • CVRx is a commercial-stage medical device company.
  • Barostim is approved for heart failure treatment in the U.S.
  • The device applies electrical pulses to carotid artery baroreceptors.
  • CPT Category I codes indicate established medical procedures.
  • Barostim received FDA Breakthrough Device designation.

Companies Mentioned

  • CVRx, Inc. (CVRX): CVRX's changes in coding enhance reimbursement prospects.

Corporate Developments

CVRx's shift to Category I CPT codes represents a vital regulatory milestone that can promote the adoption of its Barostim device. This transition addresses reimbursement issues, crucial for the growth of medical technology firms in healthcare.

FAQ

Why Bullish?

The move to Category I CPT codes is likely to enhance the marketability of Barostim, reminiscent of similar cases in other medical sectors where coding changes led to increased sales and market penetration.

How important is it?

The relevance of the CPT code change indicates a strong likelihood of increased revenue, making it a significant factor for CVRX's stock performance.

Why Short Term?

Immediate impact likely due to the recent coding changes facilitating quicker adoption of Barostim procedures.

Related Companies

MDTZBHABT

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

Minneapolis, January 6, 2026 - CVRx, Inc. (NASDAQ: CVRX), a leading medical device company focused on innovative neuromodulation therapies for cardiovascular diseases, has announced the implementation of new Category I Current Procedural Terminology (CPT) codes for its Barostim therapy. This crucial update took effect on January 1, 2026, replacing the previous Category III codes.

Significance of New CPT Codes for Barostim Therapy

The transition to Category I CPT codes is a significant advancement for CVRx and the healthcare community. In the U.S. healthcare system, Category I codes represent established medical procedures, which are essential for facilitating adoption, coverage, and reimbursement.

Healthcare providers using Barostim therapy are encouraged to update their billing systems to incorporate these new codes for all procedures conducted from January 1, 2026, onward. The new coding information is available in CVRx’s reimbursement guide and on the company’s official website.

Impact on Reimbursement and Patient Care

Kevin Hykes, President and Chief Executive Officer of CVRx, emphasized the importance of these changes: “We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals, and validate the important role of Barostim therapy in the heart failure treatment continuum.”

This transition is expected to enhance the accessibility and sustainability of Barostim therapy, benefitting both patients suffering from heart failure and the healthcare providers that care for them.

About CVRx and Barostim Technology

CVRx is committed to advancing medical technologies that improve patient outcomes in cardiovascular health. The Barostim device is the first neural modulation technology recognized by the FDA for alleviating symptoms in heart failure patients. It works by delivering electrical pulses to baroreceptors located in the carotid artery, aiming to restore balance within the autonomic nervous system.

  • Barostim received the FDA Breakthrough Device designation.
  • The device is FDA-approved for heart failure patients in the United States.
  • It complies with EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension treatments in the European Economic Area.

For additional details about Barostim, please visit www.cvrx.com.

Forward-Looking Statements

This press release may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements reflect current expectations concerning future events and are subject to inherent risks, uncertainties, and assumptions that may differ significantly from actual outcomes.

CVRx does not intend to update any forward-looking statements unless required by law. For investor inquiries, please contact:

  • Mark Klausner or Mike Vallie - ICR Healthcare
  • Phone: 443-213-0501
  • Email: ir@cvrx.com

For media inquiries, contact:

Related News